[{"id":"03b258b9-b6b1-4be5-9722-9374ceff289d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03917043","created_at":"2021-09-06T03:53:55.845Z","updated_at":"2024-07-02T16:35:28.475Z","phase":"Phase 1","brief_title":"APG-2449 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03917043","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-2449"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-11-21"}]